18F-fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging of malignant pleural mesothelioma: Radiology - Pictorial essay

Journal of Medical Imaging and Radiation Oncology

Volumn 53, Issue 2, 2009, Pages 160-169

  Subramaniam, Rm ^a,d   Wilcox, B ^b   Aubry, Mc ^c   Jett, J ^b   Peller, Pj ^a  

^a Department of Radiology ^*  (United States)

^b Division of Pulmonary and Critical Care Medicine

^c MAYO CLINIC   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

FDG; Mesothelioma; PET CT

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; PEMETREXED; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

CANCER STAGING; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; HUMAN; METASTASIS; PATHOPHYSIOLOGY; PATIENT SELECTION; PLEURA MESOTHELIOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; COMPUTER ASSISTED TOMOGRAPHY; MESOTHELIOMA; METHODOLOGY; PLEURA TUMOR; SCINTISCANNING;

FLUORODEOXYGLUCOSE F18; HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 66249102670     PISSN: 17549477     EISSN: 17549485     Source Type: Journal    
DOI: 10.1111/j.1754-9485.2009.02058.x     Document Type: Review

References (46)

1. Antman K. Natural history and epidemiology of malignant mesothelioma. Chest 1993 103 : 373S.
2. Qureshi N, Gleeson F. Imaging of pleural disease. Clin Chest Med 2006 27 : 193 213.
3. Gulmez I, Kart L, Buyukoglan H et al. Evaluation of malignant mesothelioma in central Anatolia: a study of 67 cases. Can Respir J 2004 11 : 287.
4. Baris Y, Simonato L, Artvinli M et al. Epidemiological and environmental evidence of the health effects of exposure to erionite fibres. Int J Cancer 1987 39 : 10 17.
5. Comin C, de Klerk N, Henderson D. Malignant mesothelioma. Ultrastruct Pathol 1997 21 : 315 20.
6. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995 108 : 1122 8.
7. Rusch VW. A proposed new International TNM Staging System for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer 1996 14 : 1 12.
8. Budde L, Hanna N. Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma. Expert Rev Anticancer Ther 2004 4 : 361 8.
9. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003 21 : 2636 44.
10. Sugarbaker D, Flores R, Jaklitsch M et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999 117 : 54 63. Discussion 63-5.
11. Robinson B, Musk A, Lake R. Malignant mesothelioma. Lancet 2005 366 : 397 409.
12. Hansen J, de Klerk N, Musk A, Hobbs M. Environmental exposure to crocidolite and mesothelioma. Exposure-response relationships. Am J Respir Crit Care Med 1998 157 : 69.
13. Carbone M, Pass H, Rizzo P et al. Simian virus 40-like DNA sequences in human pleural mesothelioma. Oncogene 1994 9 : 1781 90.
14. Carbone M, Pass H. Evolving aspects of mesothelioma carcionogenesis: SV40 and genetic predisposition. J Thorac Oncol 2006 1 : 169 71.
15. Gazdar A, Carbone M. Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40. Clin Lung Cancer 2003 5 : 177 81.
16. Lee Y, Light R, Musk A. Management of malignant pleural mesothelioma: a critical review. Curr Opin Pulm Med 2000 6 : 267 74.
17. Robinson BWS, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005 353 : 1591 603.
18. Heelan R, Rusch V, Begg C et al. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. AJR Am J Roentgenol 1999 172 : 1039 47.
19. Flores R, Akhurst T, Gonen M et al. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2003 126 : 11 16.
20. Schneider D, Clary-Macy C, Challa S et al. Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2000 120 : 128 33.
21. Erasmus JJ, Truong MT, Smythe WR et al. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: staging implications. J Thorac Cardiovasc Surg 2005 129 : 1363 9.
22. Krüger S, Pauls S, Mottaghy F et al. Integrated FDG PET-CT imaging improves staging in malignant pleural mesothelioma. Nuklearmedizin 2007 46 : 239 43.
23. Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest 1998 114 : 713 22.
24. Duysinx B, Nguyen D, Louis R et al. Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging. Chest 2004 125 : 489 93.
25. Kramer H, Pieterman RM, Slebos D-J et al. PET for the evaluation of pleural thickening observed on CT. J Nucl Med 2004 45 : 995 8.
26. Gerbaudo V. 18F-FDG imaging of malignant pleural mesothelioma: scientiam impendere vero... Nucl Med Commun 2003 24 : 609 14.
27. Gerbaudo VH, Sugarbaker DJ, Britz-Cunningham S, Di Carli MF, Mauceri C, Treves ST. Assessment of malignant pleural mesothelioma with 18F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology. J Nucl Med 2002 43 : 1144 9.
28. Kwek BH, Aquino SL, Fischman AJ. Fluorodeoxyglucose positron emission tomography and CT after talc pleurodesis. Chest 2004 125 : 2356 60.
29. Patz EJ, Shaffer K, Piwnica-Worms D et al. Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability. AJR Am J Roentgenol 1992 159 : 961 6.
30. Sugarbaker DJ, Strauss GM, Lynch TJ et al. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol 1993 11 : 1172 8.
31. Marom E, Erasmus J, Pass H, Patz E. The role of imaging in malignant pleural mesothelioma. Semin Oncol 2002 29 : 26 35.
32. Nowak A, Francis R, Byrne M et al. Use of 18F-FDG PET imaging in staging and prediction of survival for malignant pleural mesothelioma (MPM). Lung Cancer 2006 54 (Suppl 1 S19.
33. Janne P. Chemotherapy for malignant pleural mesothelioma. Clin Lung Cancer 2003 5 : 98 106.
34. van Meerbeeck JP, Gaafar R, Manegold C et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005 23 : 6881 9.
35. Flores RM, Akhurst T, Gonen M et al. Positron emission tomography predicts survival in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2006 132 : 763 8.
36. Gerbaudo VH, Britz-Cunningham S, Sugarbaker DJ, Treves ST. Metabolic significance of the pattern, intensity and kinetics of 18F-FDG uptake in malignant pleural mesothelioma. Thorax 2003 58 : 1077 82.
37. Wang Z, Reddy G, Gotway M et al. Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics 2004 24 : 105 19.
38. Tyszko SM, Marano GD, Tallaksen RJ, Gyure KA. Best cases from the AFIP: malignant mesothelioma. Radiographics 2007 27 : 259 64.
39. Rusch V, Piantadosi S, Holmes E. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. J Thorac Cardiovasc Surg 1991 102 : 1 9.
40. Ahamad A, Stevens C, Smythe W et al. Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest. Cancer J 2003 9 : 476 84.
41. Ung Y, Yu E, Falkson C, Haynes A, Stys-Norman D, Evans W. The role of radiation therapy in malignant pleural mesothelioma: a systematic review. Radiother Oncol 2006 80 : 13 18.
42. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004 15 : 257 60.
43. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006 354 : 496 507.
44. Ceresoli GL, Chiti A, Zucali PA et al. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose. J Clin Oncol 2006 24 : 4587 93.
45. Steinert HC, Dellea MMS, Burger C, Stahel R. Therapy response evaluation in malignant pleural mesothelioma with integrated PET-CT imaging. Lung Cancer 2005 49 : S33 5.
46. Francis RJ, Byrne MJ, van der Schaaf AA et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med 2007 48 : 1449 58.